Xencor (XNCR) EBITDA Margin (2013 - 2026)
Xencor's (XNCR) quarterly EBITDA Margin came in at 1724.14% in Q1 2026, down 159221.0% year-on-year from N/an in Q1 2025, and down 807.82% on a QoQ basis from 189.92% in Q4 2025.
Xencor (XNCR) EBITDA Margin (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of EBITDA Margin data on file, last reported at 1724.14% in Q1 2026.
- On a quarterly basis, EBITDA Margin fell 159221.0% year-over-year to 1724.14% in Q1 2026; TTM through Mar 2026 was 217.93%, a 8673.0% decrease from a year earlier, with the FY2025 full-year figure at 141.35%, up 2012.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 1724.14%, down from 189.92% in the prior quarter.
- Over the last five years, EBITDA Margin for XNCR reached as high as 30.96% in Q1 2022 and fell as low as 1724.14% in Q1 2026.
- Historically, EBITDA Margin has averaged 242.2% across 5 years, with a median of 140.47% in 2022.
- Across the five-year window, EBITDA Margin surged 20978 bps in 2025 and sank 159221 bps in 2026, its largest moves.
- Year by year, EBITDA Margin stood at 197.1% in 2022, then soared by 73 bps to 53.61% in 2023, then jumped by 53 bps to 24.96% in 2024, then sank by 661 bps to 189.92% in 2025, then sank by 808 bps to 1724.14% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 1724.14% in Q1 2026, 189.92% in Q4 2025, and 226.29% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Xencor | 1.47 Bn | 1.09 Bn | - | -1,724.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,724.14% |
| Dec 31, 2025 | -189.92% |
| Sep 30, 2025 | -226.29% |
| Jun 30, 2025 | -76.07% |
| Mar 31, 2025 | -131.93% |
| Dec 31, 2024 | -24.96% |
| Sep 30, 2024 | -310.17% |
| Jun 30, 2024 | -231.61% |
| Mar 31, 2024 | -341.71% |
| Dec 31, 2023 | -53.61% |
| Sep 30, 2023 | -30.86% |
| Jun 30, 2023 | -57.14% |
| Mar 31, 2023 | -319.71% |
| Dec 31, 2022 | -197.10% |
| Sep 30, 2022 | -140.47% |
| Jun 30, 2022 | -92.72% |
| Mar 31, 2022 | 30.96% |
| Dec 31, 2021 | 59.51% |
| Sep 30, 2021 | -209.83% |
| Jun 30, 2021 | 13.47% |